{"id":22131,"date":"2025-11-03T22:00:22","date_gmt":"2025-11-03T22:00:22","guid":{"rendered":"https:\/\/businesstriumphs.com\/index.php\/2025\/11\/03\/kimberly-clark-to-buy-kenvue-in-48-7-billion-deal\/"},"modified":"2025-11-03T22:00:22","modified_gmt":"2025-11-03T22:00:22","slug":"kimberly-clark-to-buy-kenvue-in-48-7-billion-deal","status":"publish","type":"post","link":"https:\/\/businesstriumphs.com\/index.php\/2025\/11\/03\/kimberly-clark-to-buy-kenvue-in-48-7-billion-deal\/","title":{"rendered":"Kimberly-Clark to buy Kenvue in $48.7 billion deal"},"content":{"rendered":"<p class=\"body-graf\">Kimberly-Clark said on Monday it will buy Tylenol maker Kenvue KVUE.N in a cash-and-stock deal valued at about $48.7 billion, to create one of the biggest consumer health goods companies in the United States.<\/p>\n<p class=\"body-graf\">Shares of Kenvue were up 18% in premarket trading, while Kimberly-Clark\u2018s shares were down 12.5%.<\/p>\n<div><\/div>\n<p class=\"body-graf\">Kenvue has been under a strategic review, leadership shake-up, and mounting litigation risks. It came under fresh scrutiny following President Donald Trump\u2019s comments linking its popular pain medicine Tylenol to autism.<\/p>\n<p class=\"body-graf\">The deal will bring together brands including Neutrogena, Huggies and Kleenex under a consumer health and personal care company with expected combined annual revenues of roughly $32 billion.<\/p>\n<p class=\"body-graf\">Sources in June told Reuters the strategic review of its operations could include a sale or breakup of the company that had been spun off from healthcare conglomerate Johnson &amp; Johnson JNJ.N in 2023.<\/p>\n<p class=\"endmark body-graf\">Kenvue\u2018s shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held. That implies a per-share deal value of $21.01, or an equity value of $40.32 billion, according to Reuters calculations.<\/p>\n<\/p>\n<div>This post appeared first on NBC NEWS<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kimberly-Clark said on Monday it will buy Tylenol maker Kenvue KVUE.N in a cash-and-stock deal valued at about $48.7 billion, to create one of the biggest consumer health goods companies in the United States. Shares of Kenvue were up 18% in premarket trading, while Kimberly-Clark\u2018s shares were down 12.5%. Kenvue has been under a strategic [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":22132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-22131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"_links":{"self":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/posts\/22131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/comments?post=22131"}],"version-history":[{"count":0,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/posts\/22131\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/media\/22132"}],"wp:attachment":[{"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/media?parent=22131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/categories?post=22131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/businesstriumphs.com\/index.php\/wp-json\/wp\/v2\/tags?post=22131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}